Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 258

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 258
---
 is or may be equal to 20% or more of the common stock, or 20% or more of the voting power, outstanding before the issuance.

Upon the consummation of the Business Combination, ParentCo expects to issue, in the aggregate, an estimated 19,000,000 shares of ParentCo Common Stock to the direct and indirect owners of Liminatus and the PIPE Investor, collectively, in connection with the Business Combination and the PIPE Equity Investment (excluding, for this purpose, additional securities issuable to holders of ParentCo Public Warrants, ParentCo Private Placement Warrants, and the additional shares of ParentCo Common Stock that will, upon closing, be reserved for issuance pursuant to the Incentive Plan). For further details, see “ Proposal No. 1 — The Business Combination Proposal — The Business Combination Agreement — Consideration, ” “ Proposal No. 1 — The Business Combination Proposal — Additional Agreements Executed at the Signing of the Business Combination Agreement — PIPE Subscription Agreement ,” and “ Proposal No. 3 — the Incentive Plan Proposal. ”

Accordingly, the aggregate number of shares of ParentCo Common Stock that will be issued in connection with the Business Combination and the PIPE Equity Investment will exceed 20% of both the voting power and the shares of ParentCo Common Stock outstanding before such issuance. In addition, in the future, ParentCo will issue additional shares of ParentCo Common Stock upon exercise of the ParentCo Public Warrants and ParentCo Private Placement Warrants, in accordance with the terms of the Business Combination Agreement and as further described in this proxy statement/prospectus. There will also be shares of ParentCo Common Stock reserved for issuance under the Incentive Plan (assuming the approval of the Incentive Plan Proposal by Iris’s stockholders). For further details, see “ Proposal No. 1 — The Business Combination Proposal — The Business Combination Agreement — Consideration, ” and “ Proposal No. 3 — The Incentive Plan Proposal .”

<div align='center'>124</div>

TABLE OF CONTENTS

#### Effect of Proposal on Current Stockholders
In the event that this Proposal is not approved by Iris’s stockholders, the Business Combination cannot be consummated. In the event that this Proposal is approved by Iris’s stockholders, but the Business Combination Agreement is terminated (without the Business Combination being consummated) prior to the issuance of shares of ParentCo Common Stock pursuant to the Business Combination Agreement, ParentCo will not issue such shares of Parent